What does PHARMA MANUFACTURING do?

PHARMA MANUFACTURING is registered with the CBE as active in: Activiteiten van verpakkingsbedrijven. Public Limited, started on 16 July 2001, 1 establishment.

What is the address of PHARMA MANUFACTURING?

The registered office of PHARMA MANUFACTURING is located at Rue Guillaume Fouquet,Isnes 16, 5032 Gembloux.

Is PHARMA MANUFACTURING still active?

Yes. According to the CBE (30 October 2026) PHARMA MANUFACTURING is active, legal situation “Normale toestand”, started on 16 July 2001.

Is PHARMA MANUFACTURING registered on Peppol?

Yes, PHARMA MANUFACTURING is registered on the Peppol network with ID 0208:0475313955.

What is the enterprise number of PHARMA MANUFACTURING?

The enterprise number of PHARMA MANUFACTURING is BE0475313955.

When was PHARMA MANUFACTURING founded?

PHARMA MANUFACTURING was founded on 16 July 2001.

Who owns PHARMA MANUFACTURING?

The shares are held by Jean-Charles Genette (26.6%), Olivier Genette (26.6%), Hugues Genette (26.6%), Avixia (10%), Superphar SRL (10%) and Philippe GENETTE (0.2%).

Is PHARMA MANUFACTURING a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 July 2001; 5 annual accounts filed, latest fiscal year 2025.

How much profit did PHARMA MANUFACTURING make in 2025?

PHARMA MANUFACTURING posted a profit after taxes of € 6,229 in financial year 2025.

What is the revenue of PHARMA MANUFACTURING?

In its most recent annual accounts (2025), PHARMA MANUFACTURING reported revenue of € 3,023,045.

How much does an employee at PHARMA MANUFACTURING earn?

The average wage cost per full-time employee at PHARMA MANUFACTURING was € 51,100 in 2025: staff costs of € 577,738 for 11.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA MANUFACTURING have?

According to the 2025 annual accounts, PHARMA MANUFACTURING has 11.3 full-time equivalents (FTE).

Does PHARMA MANUFACTURING have a website?

Yes, PHARMA MANUFACTURING has a website at pharma-manufacturing.be.

PHARMA MANUFACTURING (Public Limited) - Gembloux

Dossier PHARMA MANUFACTURING, printed on 30 October 2026 from databakkes.be/en/0475313955/pharma-manufacturing. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA MANUFACTURING from Gembloux, company number BE0475313955, closed financial year 2025 with a result of € 6,229 after tax. For that financial year PHARMA MANUFACTURING recorded revenue of € 3 million and equity of € 2.8 million. Compared with financial year 2024, the result moved from € 2,354 to € 6,229. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.

What it is worth Growing

€ 2.8 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 6,229

▲ 165% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 76,737

▲ 102% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.7 million.

People and assets in 2025

Full-time equivalents

11.3

▲ 1.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 577,738

▲ 14% vs 2024

€ 51,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 70,826

▼ 35% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 72,405

▼ 55% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 133,125

▲ 43% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 2,919,806 Revenue 2022: € 2,919,806 First fiscal year in the series	€ 2,914,585 Revenue 2023: € 2,914,585 Unchanged (€ 2,919,806) Unfavourable step	€ 2,787,285 Revenue 2024: € 2,787,285 ▼ 4% vs 2023 (€ 2,914,585) Unfavourable step	€ 3,023,045 Revenue 2025: € 3,023,045 ▲ 8% vs 2024 (€ 2,787,285) Favourable step	▲ 8%
Gross margin	€ 1,007,304 Gross margin 2022: € 1,007,304 First fiscal year in the series	€ 746,481 Gross margin 2023: € 746,481 ▼ 26% vs 2022 (€ 1,007,304) Unfavourable step	€ 707,091 Gross margin 2024: € 707,091 ▼ 5% vs 2023 (€ 746,481) Unfavourable step	€ 773,587 Gross margin 2025: € 773,587 ▲ 9% vs 2024 (€ 707,091) Favourable step	▲ 9%
Profit after taxes	€ 338,140 Profit after taxes 2022: € 338,140 First fiscal year in the series	€ 14,276 Profit after taxes 2023: € 14,276 ▼ 96% vs 2022 (€ 338,140) Unfavourable step	€ 2,354 Profit after taxes 2024: € 2,354 ▼ 84% vs 2023 (€ 14,276) Unfavourable step	€ 6,229 Profit after taxes 2025: € 6,229 ▲ 165% vs 2024 (€ 2,354) Favourable step	▲ 165%
Equity	€ 2,737,970 Equity 2022: € 2,737,970 First fiscal year in the series	€ 2,752,185 Equity 2023: € 2,752,185 ▲ 1% vs 2022 (€ 2,737,970) Favourable step	€ 2,754,504 Equity 2024: € 2,754,504 Unchanged (€ 2,752,185) Favourable step	€ 2,765,725 Equity 2025: € 2,765,725 Unchanged (€ 2,754,504) Favourable step
Total debts	€ 177,839 Total debts 2022: € 177,839 First fiscal year in the series	€ 254,318 Total debts 2023: € 254,318 ▲ 43% vs 2022 (€ 177,839) Unfavourable step	€ 252,385 Total debts 2024: € 252,385 ▼ 1% vs 2023 (€ 254,318) Favourable step	€ 206,419 Total debts 2025: € 206,419 ▼ 18% vs 2024 (€ 252,385) Favourable step	▼ 18%
Cash	€ 110,864 Cash 2022: € 110,864 First fiscal year in the series	€ 54,739 Cash 2023: € 54,739 ▼ 51% vs 2022 (€ 110,864) Unfavourable step	€ 37,986 Cash 2024: € 37,986 ▼ 31% vs 2023 (€ 54,739) Unfavourable step	€ 76,737 Cash 2025: € 76,737 ▲ 102% vs 2024 (€ 37,986) Favourable step	▲ 102%
Land & buildings	€ 345,008 Land & buildings 2022: € 345,008 First fiscal year in the series	€ 284,791 Land & buildings 2023: € 284,791 ▼ 17% vs 2022 (€ 345,008) Unchanged	€ 203,967 Land & buildings 2024: € 203,967 ▼ 28% vs 2023 (€ 284,791) Unchanged	€ 122,272 Land & buildings 2025: € 122,272 ▼ 40% vs 2024 (€ 203,967) Unchanged	▼ 40%
Retained profit	€ 2,675,560 Retained profit 2022: € 2,675,560 First fiscal year in the series	€ 2,689,836 Retained profit 2023: € 2,689,836 ▲ 1% vs 2022 (€ 2,675,560) Favourable step	€ 2,692,190 Retained profit 2024: € 2,692,190 Unchanged (€ 2,689,836) Favourable step	€ 2,698,419 Retained profit 2025: € 2,698,419 Unchanged (€ 2,692,190) Favourable step
Balance sheet total	€ 2,915,809 Balance sheet total 2022: € 2,915,809 First fiscal year in the series	€ 3,006,502 Balance sheet total 2023: € 3,006,502 ▲ 3% vs 2022 (€ 2,915,809) Unchanged	€ 3,006,888 Balance sheet total 2024: € 3,006,888 Unchanged (€ 3,006,502) Unchanged	€ 2,972,144 Balance sheet total 2025: € 2,972,144 ▼ 1% vs 2024 (€ 3,006,888) Unchanged	▼ 1%
Employees (FTE)	9.7 Employees (FTE) 2022: 9.7 First fiscal year in the series	9.2 Employees (FTE) 2023: 9.2 ▼ 0.5 vs 2022 (9.7) Unchanged	9.6 Employees (FTE) 2024: 9.6 ▲ 0.4 vs 2023 (9.2) Unchanged	11.3 Employees (FTE) 2025: 11.3 ▲ 1.7 vs 2024 (9.6) Unchanged	▲ 1.7

Key figures of PHARMA MANUFACTURING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA MANUFACTURING?

What happened at PHARMA MANUFACTURING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 30, 2026 New annual accounts for financial year 2025: profit of € 6,229 (▲ 165% vs 2024). filed late Source: NBB ↗
Sep 20, 2001 New establishment in Gembloux. KBO
Jul 16, 2001 Start of the company according to the CBE. KBO

In short

From € 338,140 profit in 2022 to € 6,229 profit in 2025.

Paid € 65,489 in corporate taxes since 2022.

Best year ever: 2022, with € 338,140 profit.

On average € 68,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Guillaume Fouquet,Isnes 16

5032 Gembloux

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTP pharma-manufacturing.be

Technologies

Google AnalyticsPWA

Certifications & Partners

HACCP

Hosting & Email

Email provider

Self-hosted

Hosting

HOSTEUR-NET-CORE Hosteur NETWORK CORE, FR

Domain

pharma-manufacturing.be

Registered

2007-06-06

Website info

HTTPS Nee

Languages EN

Features

Contact page

Security

✗ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0475.313.955

VAT number

BE 0475.313.955

Registered office

Rue Guillaume Fouquet,Isnes 16, 5032 Gembloux

Names & denominations

PHARMA MANUFACTURING

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

16 July 2001

Peppol

Active · Active since 31 Jul 2025

Contact

pharma-manufacturing.be

Activities · NACE

Activiteiten van verpakkingsbedrijven

Verpakkingsbedrijven

Vervaardiging van gehomogeniseerde voedingspreparaten en dieetvoeding

Groothandel in andere voedingsmiddelen, neg

Overige gespecialiseerde groothandel in voedingswaren

View on CBE Public ↗ Annual accounts (NBB) ↗